Table 1.
Shifts in Renal Function Categories from Baseline to End of Therapy in Patients Treated with Telavancin
| End of Therapy CrCl Category (ml/min) | Baseline CrCl Category (ml/min) | Total | ||||||
|---|---|---|---|---|---|---|---|---|
| ≤30 | >30–40 | >40–50 | >50–60 | >60–70 | >70–80 | >80 | ||
| ≤30 | 60 (8.8) | 15 (2.2) | 8 (1.2) | 11 (1.6) | 5 (0.7) | 6 (0.9) | 4 (0.6) | 109 (15.9) |
| >30–40 | 8 (1.2) | 21 (3.1) | 10 (1.5) | 6 (0.9) | 3 (0.4) | 1 (0.1) | 9 (1.3) | 58 (8.5) |
| >40–50 | 6 (0.9) | 12 (1.8) | 19 (2.8) | 11 (1.6) | 5 (0.7) | 4 (0.6) | 3 (0.4) | 60 (8.8) |
| >50–60 | 1 (0.1) | 5 (0.7) | 16 (2.3) | 15 (2.2) | 7 (1.0) | 5 (0.7) | 12 (1.8) | 61 (8.9) |
| >60–70 | 2 (0.3) | 4 (0.6) | 8 (1.2) | 10 (1.5) | 13 (1.9) | 8 (1.2) | 12 (1.8) | 57 (8.3) |
| >70–80 | 3 (0.4) | 1 (0.1) | 3 (0.4) | 3 (0.4) | 12 (1.8) | 10 (1.5) | 12 (1.8) | 44 (6.4) |
| >80 | 0 | 1 (0.1) | 7 (1.0) | 3 (0.4) | 16 (2.3) | 12 (1.8) | 256 (37.4) | 295 (43.1) |
| Total | 80 (11.7) | 59 (8.6) | 71 (10.4) | 59 (8.6) | 61 (8.9) | 46 (6.7) | 308 (45.0) | 684 (100) |
CrCl = creatinine clearance.
The no. (%) of patients who began therapy within a baseline renal function category (displayed horizontally) and ended therapy within a renal function category (displayed vertically) is shown. White shading represents no change in renal function, dark gray shading represents improvement in renal function, and light gray shading represents worsening renal function. Patients with missing values at baseline or end of therapy were not included in the analysis.